RecruitingPhase 3NCT06282315

Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness

Studying Ankylostomiasis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Insud Pharma
Principal Investigator
Alejandro Krolewiecki, MD, LMFT
Insud Pharma
Intervention
Pre-screening Phase(drug)
Enrollment
20000 enrolled
Eligibility
5-17 years · All sexes
Timeline
20252027

Study locations (2)

Collaborators

Ghana Health Services · Kenya Medical Research Institute · Bridges to Development · Sanger Institute · Barcelona Institute for Global Health · European Union · Swiss Confederation · Fundación Mundo Sano

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06282315 on ClinicalTrials.gov

Other trials for Ankylostomiasis

Additional recruiting or active studies for the same condition.

See all trials for Ankylostomiasis

← Back to all trials